LEADER 03611nam 2200637Ia 450 001 9910459665103321 005 20200520144314.0 010 $a1-282-86609-5 010 $a9786612866098 010 $a0-7735-7562-6 035 $a(CKB)2670000000080756 035 $a(EBL)3332018 035 $a(SSID)ssj0000478417 035 $a(PQKBManifestationID)11280439 035 $a(PQKBTitleCode)TC0000478417 035 $a(PQKBWorkID)10419274 035 $a(PQKB)11162662 035 $a(CaBNvSL)slc00225703 035 $a(CEL)432889 035 $a(MiAaPQ)EBC3271321 035 $a(MiAaPQ)EBC3332018 035 $a(Au-PeEL)EBL3332018 035 $a(CaPaEBR)ebr10558967 035 $a(CaONFJC)MIL286609 035 $a(OCoLC)923233784 035 $a(EXLCZ)992670000000080756 100 $a20070412d2007 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aHow Ottawa spends, 2007-2008$b[electronic resource] $ethe Harper Conservatives - climate of change /$fedited by G. Bruce Doern 205 $a28th ed. 210 $aMontreal, QC $cPublished for the School of Public Policy and Administration, Carleton University by McGil$dc2007 215 $a1 online resource (333 p.) 225 0 $aHow Ottawa spends 311 $a0-7735-3283-8 320 $aIncludes bibliographical references. 327 $aThe Harper conservatives in power : emissions impossible / Bruce Doern -- Addressing the fiscal imbalance through asymmetrical federalism : dangerous times for the Harper government and for Canada / Andrew Teliszewsky and Christopher Stoney -- La grande secuction : wooing Quebec / Peter Graefe and Rachel Laforest -- "Getting down to business" rebuilding Canada-U.S. relations under the Harper government / Geoffrey E. Hale -- The Federal Accountability Act : how Ottawa steps backward in monitoring political ethics and integrity / Lori Turnbull -- Why ministerial responsibility can still work / Jonathan Malloy and Scott Millar -- Room for manoeuver? The Tory agenda and Liberal commitments / Carey Anne Hill and Trevor E. Lynn -- Energy shift : Canadian energy policy under the Harper Conservatives / Keith Brownsey -- Patience! ... Wait time guarantees and conservative health care policy / Gerard W. Boychuk -- The Harper government's Universal Child Care Plan : paradoxical or purposeful social policy? / Michael J. Prince and Katherine Teghstsoonian -- Federal public service labour relations : business as usual? / Timothy J. Barkiw and Gene Swimmer -- Righting wrongs : locking them up without losing the key - Tory reforms to crime and punishment / Ian Lee -- Public-private partnerships : P3 and the "porcupine problem" / Ruth Hubbard and Giles Paquet -- Consumer protection through free markets, small government, and individual responsibility? The federal approach, 1993-2007 / Derek Ireland and Kernaghan Webb -- Appendix A : Canadian political facts and trends -- Appendix B : fiscal facts and trends. 410 0$aHow Ottawa Spends Series 606 $aGovernment spending policy$zCanada 607 $aCanada$xAppropriations and expenditures 607 $aCanada$xPolitics and government 608 $aElectronic books. 615 0$aGovernment spending policy 676 $a354.7 701 $aDoern$b G. Bruce$0901610 712 02$aCarleton University.$bSchool of Public Administration. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910459665103321 996 $aHow Ottawa spends, 2007-2008$92080424 997 $aUNINA LEADER 04120nam 22005775 450 001 9910350320203321 005 20250609110029.0 010 $a981-13-8906-3 024 7 $a10.1007/978-981-13-8906-1 035 $a(CKB)4100000009836957 035 $a(MiAaPQ)EBC5968658 035 $a(DE-He213)978-981-13-8906-1 035 $a(MiAaPQ)EBC5968253 035 $a(EXLCZ)994100000009836957 100 $a20191024d2019 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aDrug Discovery in Japan $eInvestigating the Sources of Innovation /$fedited by Sadao Nagaoka 205 $a1st ed. 2019. 210 1$aSingapore :$cSpringer Singapore :$cImprint: Springer,$d2019. 215 $a1 online resource (xv, 333 pages) $cillustrations 300 $aIncludes index. 311 08$a981-13-8905-5 327 $aForeword -- Acknowledgement -- Chapter 1: Introduction -- Chapter 2: Compactin -- Chapter 3: Pravastatin (Pravachol, Mevalotin) -- Chapter 4: Rosuvastatin(Crestor) -- Chapter 5: Leuprorelin (Leuplin, Lupron, Viadur) -- Chapter 6: Oflaxacin and levofloxacin (Tarivid/Cravit) -- Chapter 7: Tamsulosin (Harnal, Flomax, OMNIC) -- Chapter 8: Pranlukast (Onon) -- Chapter 9: Tacrolimus (Prograf) -- Chapter 10: Pioglitazone (Actos, Glustin) -- Chapter 11: Donepezil (Aricept) -- Chapter 12: Candesartan (Blopress, Atacand) -- Chapter 13: Tocilizumab (Actemra,Ro-actemra) -- Chapter 14: Nivolumab (Opdivo) -- Chapter 15: Sources of innovation of drug discovery in Japan and its implications. 330 $aThis book analyzes the drug-discovery process in Japan, based on detailed case studies of 12 groups of 15 innovative drugs. It covers the first statin in the world up to the recent major breakthrough in cancer therapy, the recent immune checkpoint inhibitor, the scientific discovery for which a 2018 Nobel Prize in Physiology or Medicine was awarded to Prof. Tasuku Honjo, Kyoto University. The book shows the pervasive high uncertainty in drug discovery: frequent occurrences of unexpected difficulties, discontinuations, serendipities, and good luck, significantly because drug discovery starts when the underlying science is incomplete. Thus, there exist dynamic interactions between scientific progress and drug discovery. High uncertainty also makes the value of an entrepreneurial scientist high. Such scientists fill the knowledge gaps by absorbing external scientific progress and by relentless pursuit of possibilities through their own research, often including unauthorized research, to overcome crises. Further, high uncertainty and its resolution significantly characterize the evolution of competition in the drug industry. The patent system promotes innovation under high uncertainty not only by enhancing appropriability of R&D investment but also by facilitating the combination of knowledge and capabilities among different firms through disclosure. Understanding such a process significantly benefits the creation of innovation management and policy practices. 606 $aEconomic policy 606 $aManagement 606 $aIndustrial management 606 $aJapan?History 606 $aR & D/Technology Policy$3https://scigraph.springernature.com/ontologies/product-market-codes/W43000 606 $aInnovation/Technology Management$3https://scigraph.springernature.com/ontologies/product-market-codes/518000 606 $aHistory of Japan$3https://scigraph.springernature.com/ontologies/product-market-codes/715020 615 0$aEconomic policy. 615 0$aManagement. 615 0$aIndustrial management. 615 0$aJapan?History. 615 14$aR & D/Technology Policy. 615 24$aInnovation/Technology Management. 615 24$aHistory of Japan. 676 $a615.190941 702 $aNagaoka$b Sadao$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910350320203321 996 $aDrug Discovery in Japan$91939025 997 $aUNINA